2024-04-10 13:29:22 ET
Summary
- Mesoblast Limited has been on a major run recently as its cell therapy candidate is back on track towards potential approval.
- The company has some upcoming potential catalysts in the quarters ahead and is advancing its pipeline on several fronts.
- However, given the company is headquartered overseas, it garners slight coverage from Wall Street and has consistently disappointed longer-term investors over the years.
- An analysis around Mesoblast follows in the paragraphs below.
Today, we take a look at Mesoblast Limited ( MESO , MEOBF, ASX:MSB ). This overseas development company has had a roller coaster ride in the market since the company got a complete response letter , or CRL, from the FDA around its marketing application for its cell therapy candidate "remestemcel-L," also known as Ryoncil, to treat a type of steroid-refractory acute graft versus host disease or sr-aGVHD in children early in August. The rejection triggered a large sell-off in the stock. However, recent positive news flow has triggered a 180-degree turn in equity. Where do the shares go from here? An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Mesoblast Limited: Back From The Dead